The concentrate of the family-owned business, founded in 1885, is definitely researching, developing, advertising and production new medications of great therapeutic value for individual and veterinary medicine. Taking social responsibility can be an important component of the corporate lifestyle at Boehringer Ingelheim. This consists of worldwide involvement in interpersonal projects, like the initiative Making even more Health and looking after the employees. Respect, equivalent opportunities and reconciling profession and family form the building blocks of the mutual cooperation. In everything it can, the ongoing company targets environmental protection and sustainability. In 2013, Boehringer Ingelheim achieved net sales around 14.1 billion euros. R&D expenditure corresponds to 19.5 percent of its net sales..Funds will be used to continue development of the Articulinx spacer technology, also to fund ongoing procedures. ‘We are very very happy to have two such experienced traders partnering with us to build up and commercialize products for the treatment of osteoarthritis, the most typical osteo-arthritis worldwide.’ The Company’s first product, the Articulinx CMC Spacer, is definitely implanted through a little incision under local anesthesia. The device works as a spacer to split up bones in joints where in fact the articular cartilage has degenerated. ‘Articulinx has made significant progress in a very capital efficient manner which is crucial in this funding environment,’ said Dr.